

**NOTICE OF CHANGE OF AUDITOR**  
Pursuant to National Instrument 51-102

TO: Davidson & Company LLP  
609 Granville Street, Suite 1200  
Vancouver, BC, V7Y 1H4

AND TO: Smythe LLP  
1700 – 475 Howe Street  
Vancouver, BC, V6C 2B3

AND TO: British Columbia Securities Commission  
Alberta Securities Commission  
Ontario Securities Commission  
Canadian Securities Exchange

Dear Sirs/Mesdames:

**RE: NOTICE REGARDING CHANGE OF AUDITOR PURSUANT TO  
NATIONAL INSTRUMENT 51-102**

Notice is hereby given, pursuant to Section 4.11 of National Instrument 51-102 – Continuous Disclosure Obligations (“**NI-51-102**”) of a change of auditor of PreveCeutical Medical Inc., (the “**Company**”).

1. Effective December 5, 2024, Smythe LLP (the “**Former Auditor**”) has resigned as auditor of the Company. The Former Auditor resigned on their own initiative.
2. Effective December 18, 2024, Davidson and Company LLP (the “**Successor Auditor**”) has been appointed as the Company’s successor auditors until the next annual general meeting of the Company.
3. The resignation of the Former Auditor and the appointment of the Successor Auditor was considered and approved by the Audit Committee of the Company’s Board of Directors and by the Company’s Board of Directors.
4. The Former Auditor did not express any modifications of opinion on its report of the Company’s financial statements relating to the fiscal years ended December 31, 2023 and December 31, 2022.
5. The Board of Directors of the Company is of the opinion that there were no “reportable events”, as defined in Section 4.11(1) of the National Instrument 51-102, between the Company and the Former Auditor which occurred in connection with the audit of the two most recently completed fiscal years or for any period subsequent to the most recently completed fiscal year for which an auditor’s report was issued.

**Dated** December 18, 2024

**PREVECEUTICAL MEDICAL INC.**

*(Signed) Stephen Van Deventer*

---

Name : Stephen Van Deventer  
Title : Chairman and CEO